9.05
price up icon1.46%   0.13
pre-market  Vorhandelsmarkt:  9.05  
loading
Schlusskurs vom Vortag:
$8.92
Offen:
$8.9
24-Stunden-Volumen:
138.00K
Relative Volume:
0.29
Marktkapitalisierung:
$167.68M
Einnahmen:
$1.54M
Nettoeinkommen (Verlust:
$-84.53M
KGV:
-1.5565
EPS:
-5.8145
Netto-Cashflow:
$-73.65M
1W Leistung:
-2.90%
1M Leistung:
+0.78%
6M Leistung:
+9.43%
1J Leistung:
-2.27%
1-Tages-Spanne:
Value
$8.79
$9.36
1-Wochen-Bereich:
Value
$8.78
$9.54
52-Wochen-Spanne:
Value
$7.12
$20.56

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile

Name
Firmenname
Corbus Pharmaceuticals Holdings Inc
Name
Telefon
617-963-0103
Name
Adresse
500 RIVER RIDGE DRIVE, NORWOOD, MA
Name
Mitarbeiter
36
Name
Twitter
@corbuspharma
Name
Nächster Verdiensttermin
2026-08-04
Name
Neueste SEC-Einreichungen
Name
CRBP's Discussions on Twitter

Compare CRBP vs VRTX, REGN, ARGX, RVMD, ONC

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
CRBP icon
CRBP
Corbus Pharmaceuticals Holdings Inc
9.05 168.23M 1.54M -84.53M -73.65M -5.8145
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
481.70 121.57B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
738.34 69.95B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
872.58 55.61B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
192.17 39.98B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
322.08 33.81B 5.76B 514.49M 1.10B 4.4813

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-30 Fortgesetzt B. Riley Securities Buy
2025-02-28 Eingeleitet William Blair Outperform
2024-12-02 Eingeleitet Piper Sandler Overweight
2024-07-30 Eingeleitet Wedbush Outperform
2024-07-22 Fortgesetzt H.C. Wainwright Buy
2024-06-26 Eingeleitet B. Riley Securities Buy
2024-06-03 Bestätigt Oppenheimer Outperform
2024-05-13 Eingeleitet RBC Capital Mkts Outperform
2024-03-06 Hochstufung Jefferies Hold → Buy
2020-09-08 Herabstufung BTIG Research Buy → Neutral
2020-09-08 Herabstufung Jefferies Buy → Hold
2020-09-08 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2020-09-08 Herabstufung ROTH Capital Buy → Neutral
2020-07-07 Eingeleitet ROTH Capital Buy
2020-06-17 Eingeleitet BTIG Research Buy
2020-03-26 Eingeleitet Nomura Buy
2019-04-05 Eingeleitet Jefferies Buy
2019-03-20 Eingeleitet Oppenheimer Outperform
2019-01-11 Bestätigt Cantor Fitzgerald Overweight
2018-12-26 Eingeleitet H.C. Wainwright Buy
2018-12-07 Eingeleitet RBC Capital Mkts Outperform
2018-10-24 Eingeleitet B. Riley FBR Buy
2018-01-19 Eingeleitet Raymond James Outperform
2017-12-14 Bestätigt Cantor Fitzgerald Overweight
2017-11-08 Bestätigt Noble Financial Buy
2017-09-29 Fortgesetzt Noble Financial Buy
2017-03-30 Bestätigt Cantor Fitzgerald Overweight
2016-11-15 Bestätigt JMP Securities Mkt Outperform
2016-11-11 Bestätigt Noble Financial Buy
Alle ansehen

Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten

pulisher
Jul 28, 2026

Corbus Pharmaceuticals (CRBP) Gains FDA Nod for Pivotal CRB-701 - GuruFocus

Jul 28, 2026
pulisher
Jul 28, 2026

Corbus Pharmaceuticals Holdings, Inc. initiates FDA-cleared registrational study for CRB-701 in oropharyngeal cancer - Traders Union

Jul 28, 2026
pulisher
Jul 28, 2026

FDA clears Corbus registrational trial for head and neck cancer drug - Investing.com Canada

Jul 28, 2026
pulisher
Jul 28, 2026

Corbus Pharmaceuticals Announces FDA Clearance to Initiate - GlobeNewswire

Jul 28, 2026
pulisher
Jul 27, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

BlackRock, Inc. (CRBP) discloses 5.9% beneficial ownership in Corbus Pharmaceuticals - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

Form 144 Corbus Pharmaceuticals Holdings For: 27 July By Investing.com - Investing.com Canada

Jul 27, 2026
pulisher
Jul 27, 2026

Corbus Pharmaceuticals Holdings Inc - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

CRBP|Corbus Pharmaceuticals Holdings Inc|Price:9.170|Chg%:-0.150 - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 26, 2026

Corbus Pharmaceuticals Market Sentiment - Benzinga España

Jul 26, 2026
pulisher
Jul 26, 2026

TradingKey - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 26, 2026
pulisher
Jul 26, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) Institutional Confidence - TradingKey

Jul 26, 2026
pulisher
Jul 24, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch

Jul 24, 2026
pulisher
Jul 24, 2026

Corbus Pharmaceuticals Holdings Inc (CRBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 23, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Jul 23, 2026
pulisher
Jul 23, 2026

Corbus Pharmaceuticals stock steadies as pipeline advances after equity raise - Ad-hoc-news.de

Jul 23, 2026
pulisher
Jul 23, 2026

Corbus Pharmaceuticals Holdings Inc. Stock Climbs 5.4%, Outperforms Peers - Bitget

Jul 23, 2026
pulisher
Jul 23, 2026

(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily

Jul 23, 2026
pulisher
Jul 21, 2026

Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch

Jul 21, 2026
pulisher
Jul 13, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Jul 13, 2026
pulisher
Jul 13, 2026

Corbus Pharmaceuticals (CRBP) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesHigh Growth Earnings - dars.gov.et

Jul 13, 2026
pulisher
Jul 13, 2026

Corbus Pharmaceuticals (CRBP) Q1 2026 Earnings: Narrower-than-Expected Loss but Stock DeclinesEarnings Quality Analysis - dars.gov.et

Jul 13, 2026
pulisher
Jul 12, 2026

Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView

Jul 12, 2026
pulisher
Jul 09, 2026

Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch

Jul 09, 2026
pulisher
Jul 08, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch

Jul 08, 2026
pulisher
Jul 07, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 07, 2026
pulisher
Jul 07, 2026

Corbus Pharmaceuticals (CRBP) Surges 4.22% as Shares Test Key ResistanceOvervalued Signals - dars.gov.et

Jul 07, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as chief medical officer - MSN

Jul 06, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer - citybiz

Jul 06, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer - marketscreener.com

Jul 06, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com - Investing.com South Africa

Jul 06, 2026
pulisher
Jul 06, 2026

Leonardo Viana Nicacio appointed as chief medical officer at Corbus Pharmaceuticals Holdings, Inc. - Traders Union

Jul 06, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals Appoints CMO Amid Key Trial Launches - TipRanks

Jul 06, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals names Leonardo Nicacio as CMO - Investing.com

Jul 06, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines - Stock Titan

Jul 06, 2026
pulisher
Jul 06, 2026

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - The Manila Times

Jul 06, 2026
pulisher
Jul 03, 2026

Corbus Pharmaceuticals outlines its immuno-oncology strategy as a clinical-stage biotech - Ad-hoc-news.de

Jul 03, 2026
pulisher
Jul 02, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Jul 02, 2026
pulisher
Jul 02, 2026

CRBP issuer: affiliate Dominic Smethurst plans resale of 23,025 shares (CRBP) - Stock Titan

Jul 02, 2026
pulisher
Jul 01, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Jul 01, 2026
pulisher
Jun 30, 2026

(CRBP) Risk Channels and Responsive Allocation - Stock Traders Daily

Jun 30, 2026
pulisher
Jun 30, 2026

HPV positive oropharyngeal cancer strategy accelerates with new CRB-701 data at Corbus Pharmaceuticals Holdings, Inc. - Traders Union

Jun 30, 2026
pulisher
Jun 29, 2026

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026
pulisher
Jun 29, 2026

CRBP Q1 2026 Earnings: EPS Beats Estimates Amid Pipeline ProgressAnalyst Consensus Shift - dars.gov.et

Jun 29, 2026
pulisher
Jun 29, 2026

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026
pulisher
Jun 28, 2026

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Completeness Index - marketscreener.com

Jun 28, 2026

Finanzdaten der Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Corbus Pharmaceuticals Holdings Inc-Aktie (CRBP) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Kung Winston
Director
Jun 10 '26
Sale
7.91
2,026
16,033
12,140
Altmeyer Anne
Director
Jun 10 '26
Sale
7.91
2,412
19,088
7,579
Jenkins John Kenneth
Director
Jun 10 '26
Sale
7.91
4,800
37,986
3,833
Saxena Nishant C
Chief Business Officer
Jun 03 '26
Buy
7.58
9,000
68,220
75,300
Saxena Nishant C
Chief Business Officer
Jun 02 '26
Buy
7.33
4,500
32,998
66,300
Smethurst Dominic
Chief Medical Officer
Mar 02 '26
Sale
8.30
6,097
50,601
89,790
$92.85
price down icon 0.11%
$122.99
price down icon 3.23%
$34.52
price up icon 5.02%
$59.02
price down icon 0.27%
$205.48
price down icon 28.31%
ONC ONC
$322.08
price down icon 1.57%
Kapitalisierung:     |  Volumen (24h):